These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 10361449)

  • 1. [Efficacy of angiotensin II receptor antagonists as a novel drug for the treatment of chronic heart failure--in comparison with ACE inhibitors].
    Kitakaze M; Kuzuya T; Hori M
    Nihon Rinsho; 1999 May; 57(5):1148-57. PubMed ID: 10361449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interactions of angiotensin-converting enzyme, kinins and nitric oxide in circulation and the beneficial effects of ACE inhibitors in cardiovascular diseases.
    Magen E; Viskoper RJ
    Isr Med Assoc J; 2000 Dec; 2(12):929-34. PubMed ID: 11344778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale for the use of combination angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker therapy in heart failure.
    Carson PE
    Am Heart J; 2000 Sep; 140(3):361-6. PubMed ID: 10966531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Renin-angiotensin system as a potential target for the treatment with heart failure: ACE inhibitors, angiotensin-II receptor blockers and aldosterone antagonists].
    Sanada S; Kitakaze M
    Nihon Rinsho; 2003 May; 61(5):821-6. PubMed ID: 12755009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of heart failure caused by left ventricular systolic dysfunction.
    Sander GE; McKinnie JJ; Greenberg SS; Giles TD
    Prog Cardiovasc Dis; 1999; 41(4):265-300. PubMed ID: 10362349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress in the development of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Singh RK; Barker S
    Curr Opin Investig Drugs; 2005 Mar; 6(3):269-74. PubMed ID: 15816503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Theoretical basis for the use of angiotensin II antagonists in the treatment of heart failure.
    Chang PI; Pitt B
    Cardiologia; 1994 Dec; 39(12 Suppl 1):409-11. PubMed ID: 7634306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.
    Dieterich HA; Wendt C; Saborowski F
    Fiziol Cheloveka; 2005; 31(6):97-105. PubMed ID: 16366159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The renin-angiotensin-aldosterone system and heart failure.
    Sayer G; Bhat G
    Cardiol Clin; 2014 Feb; 32(1):21-32, vii. PubMed ID: 24286576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure.
    Bauersachs J; Fraccarollo D
    Minerva Cardioangiol; 2003 Apr; 51(2):155-64. PubMed ID: 12783071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition.
    van de Wal RM; Plokker HW; Lok DJ; Boomsma F; van der Horst FA; van Veldhuisen DJ; van Gilst WH; Voors AA
    Int J Cardiol; 2006 Jan; 106(3):367-72. PubMed ID: 16337046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The influence of ACE inhibitors on urinary electrolyte secretion and the response to transitory hypovolemia in chronic heart failure].
    Marenzi G; Lauri G; Assanelli E; Grazi M; Guazzi M; Berna G; Salvioni A; Agostoni P
    Cardiologia; 1997 Dec; 42(12):1277-83. PubMed ID: 9534323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of heart failure based on large-scale clinical trials: renin-angiotensin system antagonists and beta-blockers].
    Kubota T; Takeshita A
    Nihon Rinsho; 2003 May; 61(5):801-6. PubMed ID: 12755006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinin and angiotensin II receptor antagonists in rats with chronic renal failure: chronic effects on cardio- and renoprotection of angiotensin converting enzyme inhibitors.
    Kohzuki M; Kanazawa M; Liu PF; Kamimoto M; Yoshida K; Saito T; Yasujima M; Sato T; Abe K
    J Hypertens; 1995 Dec; 13(12 Pt 2):1785-90. PubMed ID: 8903652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of the renin-angiotensin-aldosterone system in chronic heart failure: choice of agents and clinical impact.
    Jorde UP
    Cardiol Rev; 2006; 14(2):81-7. PubMed ID: 16493245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG
    J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin II receptor blockers: novel therapy for heart failure?
    Munger MA; Furniss SM
    Pharmacotherapy; 1996; 16(2 Pt 2):59S-68S. PubMed ID: 8668607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin receptor antagonists and ACE inhibitors.
    Howes LG; Christie N
    Aust Fam Physician; 1998 Oct; 27(10):914-7, 919-21. PubMed ID: 9798290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.